Drawdowns & Recovery
EMCUREAll-Time High & Drawdowns
Emcure Pharmaceuticals Ltd.
EMCURE last closed at ₹1,869, 8.7% below its all-time high of ₹2,048. The deepest fall in its record was -33.2%, and it spent 18 months below that peak.
- All-time high
- ₹2,048
- Latest close
- ₹1,869
- Below the high
- 8.7%
- Worst fall on record
- -33.2%
All-Time High
EMCURE all-time high price
The highest price EMCURE has ever traded at is ₹2,048, first reached on 10 August 2026. It last closed at ₹1,869, which is 8.7% below it.
- All-time high
- ₹2,048
- Reached
- 10 August 2026
- Distance today
- -8.7%
Measured on intraday highs adjusted for stock splits but not for dividends — the basis on which prices are quoted, so this is directly comparable with the price on your screen. It is deliberately a different measurement from the drawdown below, which is a total-return figure.
Trailing Year
EMCURE 52-week high and low
Over the last twelve months EMCURE has traded between ₹1,260 and ₹2,048, and sits 8.7% below the top of that range.
The window is the twelve months ending 2026-08-31. Figures refresh when our data pipeline runs, not continuously — this is a research record, not a live quote.
The Worst Fall
The biggest fall EMCURE has ever had
The deepest drawdown in Emcure Pharmaceuticals Ltd.'s record is -33.2% — from a peak in September 2024 to a low in February 2025, a fall that took 5 months. That is the loss an investor holding throughout would have been looking at on paper, with dividends counted as reinvested.
- Peak
- September 2024
- Trough
- February 2025
- Fall
- -33.2%
- Recovered
- March 2026
It took until March 2026 to get back above the September 2024 peak — 1 year and 6 months underwater in total. Anyone who sold at the bottom locked in the -33.2%; anyone who held got it all back and kept whatever came afterwards.
Measured on month-end values, so a fall that went deeper inside a month and came back before month end is not captured — a real intra-month low was at least this bad and possibly worse. Dividends are treated as reinvested, which makes this shallower than the fall in the quoted price.
Recovery
How long EMCURE took to recover
Depth is only half of a drawdown. The part that decides whether someone holds on is how long they spend waiting to get back to where they were.
The worst stretch
EMCURE spent 1 year and 6 months below its previous peak during the -33.2% fall, finally clearing it in March 2026. The climb back from the bottom alone took 1 year and 1 month.
Where it stands now
On a total-return basis EMCURE sits 4.6% below its best month, which was July 2026 — 1 month ago.
These figures are total return — the peak is the high point of a holding whose dividends were reinvested, which is not the same as the highest quoted price. The quoted-price figures are in the all-time-high section above, and the two will differ on any company that pays a dividend.
How This Is Calculated
Reading these figures properly
Two different bases
The all-time high and 52-week range are quoted prices — split-adjusted, dividends excluded. The drawdown and recovery figures are total return, with dividends reinvested. On a dividend payer they will not agree, and that difference is the dividends rather than an error.
Month-end drawdowns
The fall and recovery are measured on month-end values, so a deeper low inside a month that recovered before the month closed is not captured. The real worst moment was at least this bad.
Not a live quote
Figures refresh when our data pipeline runs, not tick by tick. This is a research record of what has happened, and it is not intended for trading decisions.
Measured on data to 2026-08-31, from 2024-07-01. Full definitions are on our methodology page.
HELP CENTER
EMCURE all-time high and drawdowns — common questions
Everything you need to know about this page and the data presented.
What is the all-time high of EMCURE?+
₹2,048, first reached on 10 August 2026. Emcure Pharmaceuticals Ltd. last closed at ₹1,869, which is 8.7% below it. This is an intraday high adjusted for stock splits but not for dividends, so it is directly comparable with the price quoted today. Figures update when our data pipeline runs rather than continuously.
How far is EMCURE from its all-time high?+
8.7% below it. Recovering that would take a gain of about 9.6% from here — the asymmetry that makes falls harder to undo than they look, because a 50% fall needs a 100% gain to reverse.
What is the 52-week high and low of EMCURE?+
Over the last twelve months Emcure Pharmaceuticals Ltd. traded between ₹1,260 and ₹2,048, and last closed at ₹1,869. Both figures are intraday — the highest and lowest prices actually printed in the window, not the highest and lowest closes.
What is the biggest fall EMCURE has ever had?+
-33.2%, from a peak in September 2024 to a low in February 2025. That is measured on total return, so dividends are counted as reinvested and the fall in the quoted price was deeper still. It is also measured on month-end values, which means an intra-month low that recovered before the month closed is not captured — the real worst moment was at least this bad.
How long did EMCURE take to recover from its worst fall?+
1 year and 6 months. It fell from its September 2024 peak, bottomed in February 2025, and did not close a month above the old peak again until March 2026 — the climb back from the bottom alone took 1 year and 1 month. Depth gets the attention, but the waiting is what most people find hard.
Why does this page show two different all-time highs?+
Because they measure different things and both are correct. The ₹2,048 figure is a price — the highest EMCURE ever traded at, on the same basis prices are quoted today. The drawdown section instead tracks the value of a holding whose dividends were reinvested, and its peak is the high point of that holding rather than of the price. On a company that pays dividends the two always differ, and using the second one to answer "what is the all-time high" would understate it.
Is EMCURE a good buy after this fall?+
That is not a question this page answers, and we do not make recommendations. What it can tell you is exactly how far Emcure Pharmaceuticals Ltd. has fallen from its high, how deep its worst fall was, and how long the recovery took — the historical context most price pages leave out. A stock that recovered from every previous fall may not recover from this one, and a large fall is not by itself evidence of value. ReturnScreener is an educational research platform and is not a SEBI-registered investment adviser.
Explore Further
More on Emcure Pharmaceuticals Ltd.
EMCURE rolling returns
Every holding period on record — the best, the worst and the median.
EMCURE SIP returns
What a monthly investment through those falls would have produced.
EMCURE overview
Price history, wealth journey and how it compares with the index.
Stocks furthest below their highs
The whole universe ranked by distance from the all-time high.
ReturnScreener is an educational research platform and is not a SEBI-registered investment adviser. Everything on this page is a record of what historical prices did, not a projection and not a recommendation. A large fall is not by itself evidence of value. Past performance does not guarantee future returns. See our methodology and disclaimer.